HOOK: HOOKIPA Growth-Adjusted Market Cap to Net Income
The reliability of HOOKIPA Pharma Inc. (HOOK) is based on partnerships with tech giants and the Vaxwave platform. Tracking the PEG momentum indicator on GURU.Markets, we note that 0.00 serves as the current value of the parameter. However, intense competition in immunotherapy creates risks, while the lack of stable cash flow due to R&D expenditures limits the business's current momentum.
Metric breakdowns and analytics for HOOKIPA Pharma Inc. (HOOK)
- share price and consensus valuation forecast:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital HOOKIPA Pharma Inc.|HOOK - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio hookipapharma.com|HOOK - Company Aggregate Debts|Debts to Book Value HOOKIPA|HOOK - Company Long-Term Debts|Company Short-Term Loans and Borrowings HOOKIPA Pharma|Immediate Liquidity hookipapharma.com
- business earnings and investment ratios data:
HOOK - Company Net Income|Expected Net Profit HOOKIPA Pharma Inc.|HOOK - Price to Earnings Ratio|Forward P/E Multiple hookipapharma.com|HOOK - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio HOOKIPA|HOOK - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months HOOKIPA Pharma|HOOK - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth hookipapharma.com|HOOK - Net earnings per share growth this year|Expected earnings per share trend next year HOOKIPA Pharma Inc.
General company analysis:HOOK - HOOKIPA Pharma, Inc.
The PEG ratio compares the market value of earnings to their growth rate, where a value below one signals a fundamental undervaluation of the asset relative to its growth pace. Analyzing the P/E multiple balance and growth for HOOKIPA Pharma Inc. (HOOK) allows for an assessment of the synergy efficiency with pharma behemoths in vaccine development, confirming the company's resilience through a discount to future technological successes.
Competing companies
ARGX (argenx N.V.) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (BioNTech Group)|Growth-Adjusted Market Cap to Net Income Abivax (ABVX)|ADMA - Price/Earnings to Growth Ratio|protagonist-inc.com (PTGX) - Price/Earnings to Growth Multiple|Immunovant (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals, Ltd.|Price/Earnings to Growth Multiple GRFS|PEG Multiple Adaptive Biotechnologies Inc.|Price/Earnings to Growth Ratio Celldex Therapeutics (CLDX)|auriniapharma.com - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (BioCryst Pharmaceuticals)|Vera Therapeutics Inc (VERA) - Price to Earnings Adjusted for Growth Rate|Dianthus Pharma - PEG Multiple|Growth-Adjusted Payback Ratio PHVS (Pharvaris Pharma)|abcellera.com (ABCL) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate tourmalinebio.com (TRML)|Price/Earnings to Growth Ratio Precigen|Price to Earnings Adjusted for Growth Rate Pharming Group NV PHAR|Price/Earnings to Growth Ratio Nektar (NKTR)|PEG Multiple Upstream Pharma (UPB)|PEG Multiple ZBIO (Zenas Biopharma Inc)|Growth-Adjusted Market Cap to Net Income immunome.com (IMNM)|GOSS - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio KALV|SEPN: PEG Multiple|Pieris Corp (PVLA) - PEG Multiple|Price/Earnings to Growth Multiple SVRA|RIGL: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio AnaptysBio (ANAB)|ATXS: Market Cap to Earnings and Growth Ratio|PEG Multiple ENGN (enGene Bio)|Growth-Adjusted Payback Ratio RAPT|Aerovate - PEG Multiple|ACRS - PEG Multiple|Kyverna Therapeutics, Inc. (KYTX) - Price/Earnings to Growth Ratio|Tiziana Life Sciences Ltd. - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Cabaletta Bio, Inc|Price/Earnings to Growth Multiple Ventyx Biosciences, Inc (VTYX)|PEG Multiple THTX|PEG Multiple avalotx.com (AVTX)|Eledon Pharmaceuticals, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio AGEN|Climb Bio, Inc. - PEG Multiple|Growth-Adjusted Market Cap to Net Income zurabio.com ZURA|aTyr Pharma, Inc. (ATYR) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio ADAG|IMA (ImageneBio) - PEG Multiple|Price/Earnings to Growth Multiple Shattuck Therapeutics (STTK)|Price/Earnings to Growth Multiple EQ (Equillium, Inc.)|Growth-Adjusted Market Cap to Net Income connectbiopharm.com|PEG Multiple IMUX (Immunic)|Growth-Adjusted Payback Ratio ATRA|IFRX - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate X4 Pharmaceuticals Inc.|adicetbio.com (ACET) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Celularity (CELU)|Price/Earnings to Growth Ratio INmune Bio, Inc.|PEG Multiple barinthusbio.com|Price/Earnings to Growth Ratio Kezar Life Sciences, Inc. (KZR)|SABS: Market Cap to Earnings and Growth Ratio|PEG Multiple AKTX (Akari Therapeutics plc)|Growth-Adjusted Payback Ratio ENLV|Q32 Bio Corp - PEG Multiple|GOVX - PEG Multiple|Edesa Biotech (EDSA) - Price/Earnings to Growth Ratio|iBio Inc - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Carisma Therapeutics Inc|Price/Earnings to Growth Multiple XTL Bio (XTLB)|PEG Multiple BOLT|PEG Multiple hcwbiologics.com (HCWB)|Aptevo Therapeutics Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio AIM|Aditxt Corp - PEG Multiple|Growth-Adjusted Market Cap to Net Income GRI Bio Corporation GRI|XORTX Therapeutics Inc. (XRTX) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple reshapelifesciences.com|Price/Earnings to Growth Ratio Revelation Biosciences, Inc.|Price/Earnings to Growth Multiple Indaptus Therapeutics Inc (INDP)|Price/Earnings to Growth Multiple SCNI (Scinai)|PEG Multiple calcimedica.com (CALI)|Price/Earnings to Growth Ratio Affimed N.V. AFMD|ALLK: Growth-Adjusted P/E Ratio|IGM Bio - PEG Multiple|Price to Earnings Adjusted for Growth Rate iTeos Therapeutics Inc|OCEA: PEG Multiple|TC BioPharm Ltd - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Third Harmonic Bio
